转人内皮抑素基因双歧杆菌液抑制血管生长的实验观察

目的：研究转人内皮抑素基因双歧杆菌液对血管生长的抑制作用，并观察其对动物移植性肝癌Heps的抑瘤作用。方法：以小鼠移植性肝癌Heps建立肿瘤模型；分别进行灌胃和尾静脉注射给药，同时用转人内皮抑素基因双歧杆菌液做鸡胚绒毛尿囊膜（CAM）实验，在解剖显微镜下计数血管条数，用图像分析仪定量分析血管密度。实验动物处死后，称瘤重并计算抑瘤率。结果：转基因双歧杆菌液高、中、低3个剂量组的抑瘤率分别为49.78%、45.81%和30.41%；普通双歧杆菌组抑瘤率为10.9%，尾静脉注射转基因双歧杆菌组抑瘤率为58.3%；CAM实验显示转基因双歧杆菌液可明显抑制血管的生成。结论：转基因双歧杆菌有良好的抑制血管生长和抑制肿瘤生长的作用，且其作用有量效关系。

Transgenic bifidobacterial suspension of endostatin in inhibiting angiogenesis:an experimental observation

Objective: To study the inhibitory effect of transgenic bifidobacterial suspension of endostatin on angiogenesis and to observe its inhibitory effect on animal transplant liver cancer Heps. Methods: After the model of transplant liver cancer Heps in mice was established, transgenic bifidobacteria was given by stomach-drenching and was injected into the tumor-bearing mice via their tail veins. At the same time, the experiment of chorioallantoic membrane (CAM) was practiced by using transgenic bifidobacterial suspension of endostatin. The numbers of capillary of CAM were counted under an anatomical microscope and the density of microvessels was analyzed quantitatively by imaging analysis apparatus. After the mice were killed, the tumors of the mice were weighed and the tumor inhibitory rate were counted. Results: The tumor inhibitory rates of the transgenic bifidobacterial suspension in groups of high, medium and low dose groups were 49.78%, 45.81%, 30.41%, respectively. The tumor inhibitory rate in the group of normal bifidobacterial suspension was 10.9%, and the tumor inhibitory rate in the group of transgenic bifidobacterial suspension of endostatin injected via tail vein was 58.3%. The experiment of CAM shows that transgenic bifidobacterial suspension of endostatin can significantly inhibit angiogenesis. Conclusion: Transgenic bifidobacteria of endostatin has good effect in inhibiting angiogenesis and tumor growth, and its effect is dose-dependent.